Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)
Part of paid clinical trials in Houston, Texas.
- Sponsor
- The University of Texas Health Science Center, Houston
- Study ID
- NCT06345963
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 60 Years
- Healthy Volunteers
- Not accepted
Interventions
- active H-coil delivered rTMS — DEVICEMultiple trains of rTMS in a day, for multiple days.
Study Details
Patients with schizophrenia spectrum disorder (SSD) will be exposed to active repetitive transcranial magnetic stimulation (rTMS) from H coil for improving white matter integrity.
Key Dates
- Start date
- May 21, 2024
- Status verified
- May 2025
- Primary completion
- May 1, 2029
- Completion
- May 1, 2030
Study Design
- Enrollment
- 120 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Active rTMSParticipants in this group will receive active H-coil delivered rTMS.
Primary Outcome Measure
Brain microstructural integrity as indicated by white matter fractional anisotropy (FA) values as assessed by magnetic resonance imaging (MRI) [ Time Frame: baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline) ]
Central Contacts
- Victoria M Acosta713-486-2740
- Xiaoming Du, PhD443-882-9717
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| The University of Texas Health Science Center, Houston | Houston | Texas | 77054 |
Find similar trials in Houston, TX
By condition
By specialty
Related Studies
- Database Registry for Neural Network Biomarkers in PsychosisRecruiting · University of Texas Southwestern Medical Center · Dallas, Texas
- Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With SchizophreniaPHASE3 · Recruiting · Gedeon Richter Plc. · Culver City, California
- Ocrelizumab for Psychosis by AutoimmunityPHASE1/PHASE2 · Recruiting · The Methodist Hospital Research Institute · Houston, Texas
- CLOZAPINE Response in Biotype-1PHASE4 · Recruiting · University of Texas Southwestern Medical Center · Hartford, Connecticut